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Abstract
Background: Quetiapine causes less prolactin elevation and/or galactorrhoea than other atypical
antipsychotics.
Case Presentation: Ms AB had galactorrhoea and raised prolactin levels at only 100 mg of
quetiapine daily.
Conclusion: Low dose quetiapine can also cause galactorrhoea.
Background
Prolactin elevation and consequent galactorrhoea is a
known side effect of antipsychotics [1]. Under normal cir-
cumstances, dopamine-producing neurons in the arcuate
nucleus of the hypothalamus release dopamine in the
hypothalamo-hypophysial blood vessels of the median
eminence, which supply the pituitary gland. This
dopamine inhibits prolactin secretion. When antipsychot-
ics are taken, dopamine receptor blockade in the tuber-
oinfundibular pathway [2] releases the lactotrope cells in
the pituitary, which secrete prolactin, leading to conse-
quent hyperprolactinemia. This in turn can cause side
effects like galactorrhoea, breast enlargement, menstrual
disturbances, amenorrhoea or sexual disturbances.
Galactorrhoea is a troublesome and embarrassing side
effect of antipsychotics. Quetiapine is the least galac-
togenic antipsychotic and has been recommended as the
treatment to use if a patient has galactorrhoea on
haloperidol [3]. It has been shown to have little effect on
prolactin levels [4,5]. One report [6] mentioned substitut-
ing quetiapine for olanzapine in a client who had prol-
actinemia and consequent galactorrhoea. Quetiapine was
used in a 400 mg daily dose and both galactorrhoea and
prolactinemia subsided. This was in keeping with evi-
dence that clozapine and quetiapine are the least likely to
cause prolactinemia among the atypical antipsychotics
[7].
Keller et al [5] describe a series of five cases where they
switched to quetiapine following prolactinemia on other
atypicals and had no recurrence of endocrinological
symptoms. The E-SOHO [8] study reported lower inci-
dence of side effects related to prolactin elevation in those
treated with quetiapine, clozapine and olanzapine. A ran-
domized study in Turkey [9] showed that cohorts on
quetiapine had no prolactin elevation while two of those
on haloperidol had galactorrhoea.
One case report of galactorrhoea associated with quetiap-
ine [10], focused on the role of venlafaxine and its action
on dopamine in the brain.
Unlikely thus that it is, this case report discusses galactor-
rhoea in a client on a very low dose of quetiapine.
Published: 24 July 2007
Clinical Practice and Epidemiology in Mental Health 2007, 3:12 doi:10.1186/1745-0179-3-
12
Received: 3 January 2007
Accepted: 24 July 2007
This article is available from: http://www.cpementalhealth.com/content/3/1/12
© 2007 Gupta; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Clinical Practice and Epidemiology in Mental Health 2007, 3:12 http://www.cpementalhealth.com/content/3/1/12
Page 2 of 3
(page number not for citation purposes)
Case Presentation
Ms AB, a 31 year old lady known to be suffering from per-
sonality disorder complained of troublesome voices off
and on for the last few years. More recently she felt that
these voices were telling her to self-harm. These were pre-
sumed to be dissociative in nature and no antipsychotics
had been prescribed consistently. We added quetiapine 50
mg at night with a plan to increase the dose gradually.
However, an increase to 100 mg caused drowsiness and
the patient felt unable to increase the dose further. She
also complained of muscle spasms which improved on
procyclidine. Ten days after the increase to 100 mg, the cli-
ent complained of a feeling of heaviness in her breasts and
later of galactorrhoea. A serum prolactin estimation (17
days on 100 mg) showed raised levels (603 mu/l; N =
102–496). A retrospective medicine chart review showed
only two extra doses of 50 mg having been used in the last
week before the estimation.
I investigated a number of other potential reasons for ele-
vation of prolactin and consequent galactorrhoea. Thy-
roid stimulating hormone (TSH) level was within normal
limits. A brain scan was not performed, as the elevation
was less than two times the upper limit of normal, which
made it unlikely to be a pituitary tumour. Other medica-
tions that the client was on included divalproex sodium
1250 mg, gabapentin 900 mg and venlafaxine 150 mg.
These were on similar doses before the quetiapine was
started and after the quetiapine was stopped. At the time
of the second prolactin estimation, these were still contin-
uing with no symptoms and the prolactin levels were nor-
mal.
The quetiapine dose was reduced to 50 mg and then
stopped. The galactorrhoea subsided in three days and the
heaviness in breasts remitted in seven days.
A repeat serum prolactin estimation two months after
stopping the quetiapine showed normal levels (359 mu/l;
N = 102–496). No other antipsychotic was tried.
Discussion
Atypical antipsychotics cause less prolactin elevation and/
or galactorrhoea than typical antipsychotics [2]. Quetiap-
ine is an atypical antipsychotic that has been shown to
have transiently high dopamine (D2) receptor occupancy
[11]. This is explained as the reason for its low incidence
of extrapyramidal (EPS) and prolactin elevation. In 2002,
Kapur and scientists at Janssen Pharmaceuticals, pub-
lished results indicating that quetiapine differentially
occupied striatal and pituitary D2 receptors [12]. This
explained the less frequent association of quetiapine with
prolactin elevation. No wonder then that quetiapine is
deemed to be the least galactogenic of all atypical antipsy-
chotics.
Yet, there have been some reports of its adverse effect on
the prolactin-galactorrhoea mechanism. Alexiadis et al, in
a letter, mention elevation of prolactin due to quetiapine
within 90 minutes [13]. However, it did not report any
consequent galactorrhoea. Pae et al present a report of
quetiapine and venlafaxine leading to galactorrhoea [10].
They focus on the role of venlafaxine on dopamine and
the consequent galactorrhoea. In this case report, though
the client was on venlafaxine along with quetiapine,
galactorrhoea subsided on stopping quetiapine, while
venlafaxine continued.
An adolescent male has been reported to suffer from
galactorrhoea on standard doses of quetiapine, which
subsided on reducing the dose to 400 mg/day [14]. The
report discusses the proven lack of evidence of sympto-
matic endocrinological symptoms in adolescents with
quetiapine; and cautions that this may "rarely be encoun-
tered". It is interesting that galactorrhoea appeared after
three months of maintenance treatment and on 600 mg/
day, whereas in Ms AB it appeared within ten days and on
a low dose of only 100 mg/day.
While evidence suggests otherwise, galactorrhoea with
quetiapine may be an uncommon side effect, which needs
to be ruled out in a symptomatic patient. Clinically, emer-
gent galactorrhoea is likely to be an embarrassing and dis-
tressing iatrogenic side effect of any treatment.
Hyperprolactinemia, on the other hand may not be appar-
ent and may not lead to any dysfunction in the patient.
Quetiapine's use is acceptable when galactorrhoea does
not emerge, and patients' are likely to accept it even if pro-
lactin is elevated.
Conclusion
Quetiapine, an atypical antipsychotic, may cause galactor-
rhoea due to prolactin level elevation. In this client this
effect appeared at a very low dose of just 100 mg a day
within ten days. Stopping the antipsychotic, relieved
galactorrhoea and normalised the prolactin levels.
This case report adds to our knowledge of side effects due
to quetiapine. Clinicians may want to look at all antipsy-
chotics, including quetiapine, as possible reasons for
galactorrhoea. However, it must be realised that this is a
case report and the actual incidence might be less com-
mon.
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